Maprotiline API Manufacturers

compare suppliers & get competitive offers

To view suppliers for this material, you need to be logged in first.

This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.

Looking for Maprotiline API 10262-69-8?

Description:: Here you will find a list of producers, manufacturers and traders of Maprotiline. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:: Maprotiline
Synonyms:: Maprotilina , Maprotilinum , Maprotylina , Maprotiline hydrochloride
Cas Number:: 10262-69-8
DrugBank number:: DB00934
Unique Ingredient Identifier:: 2U1W68TROF

About Maprotiline

Do you want to know more about Maprotiline? You can find a small explanation about it here. Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake.

Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.

Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements.

Maprotiline is a type of Tricyclic antidepressants

Tricyclic antidepressants (TCAs) are a class of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the treatment of various mental health disorders, especially depression and anxiety. TCAs derive their name from their unique molecular structure, which consists of three interconnected rings.

These antidepressants work by inhibiting the reuptake of neurotransmitters such as serotonin and norepinephrine in the brain, thereby increasing their availability and improving mood regulation. Some commonly prescribed TCAs include amitriptyline, imipramine, and nortriptyline.

The efficacy of TCAs in managing depressive symptoms is well-documented, making them a popular choice among healthcare professionals. Additionally, they exhibit analgesic properties, making them useful in treating chronic pain conditions like neuropathic pain and migraines.

It is important to note that TCAs are associated with a range of side effects, including dry mouth, drowsiness, constipation, and blurred vision. Moreover, they require careful monitoring due to their potential for drug interactions, particularly with monoamine oxidase inhibitors (MAOIs) and selective serotonin reuptake inhibitors (SSRIs).

Despite the availability of newer classes of antidepressants, TCAs remain an essential component of the treatment arsenal for various mental health disorders. Their well-established efficacy, along with ongoing research and development in the field, ensures that TCAs will continue to play a significant role in managing these conditions in the foreseeable future.

Maprotiline (Tricyclic antidepressants), classified under Antidepressants

Antidepressants are a category of pharmaceutical Active Pharmaceutical Ingredients (APIs) widely used in the treatment of depression and other mood disorders. These medications work by balancing the levels of certain chemicals in the brain called neurotransmitters, such as serotonin, norepinephrine, and dopamine.

There are several types of antidepressants available, each with its own mechanism of action and efficacy. Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed as a first-line treatment for depression. They prevent the reabsorption of serotonin, resulting in increased serotonin levels in the brain. Examples of popular SSRIs include fluoxetine, sertraline, and escitalopram.

Tricyclic antidepressants (TCAs) are another class of antidepressants that work by blocking the reuptake of both serotonin and norepinephrine. They are generally used when SSRIs are ineffective or not well-tolerated. Amitriptyline, nortriptyline, and imipramine are commonly prescribed TCAs.

Other antidepressants include serotonin-norepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, and monoamine oxidase inhibitors (MAOIs). SNRIs, such as venlafaxine and duloxetine, inhibit the reuptake of both serotonin and norepinephrine. Atypical antidepressants, including bupropion and mirtazapine, have diverse mechanisms of action, targeting multiple neurotransmitters. MAOIs, such as phenelzine and tranylcypromine, work by inhibiting the enzyme monoamine oxidase, which breaks down neurotransmitters.

It is important to note that antidepressants may have various side effects and require close monitoring by healthcare professionals. Dosages and treatment duration vary based on individual needs and response. Antidepressants are typically prescribed as part of a comprehensive treatment plan that may include psychotherapy and lifestyle modifications.

In conclusion, antidepressants are a vital category of pharmaceutical APIs used to manage depression and related mood disorders. They act on neurotransmitters in the brain to alleviate symptoms and improve overall well-being. It is crucial to consult with a healthcare provider to determine the most suitable antidepressant and monitor its effects.